Shanghai Xiao Fang Pharmaceutical Co.,Ltd. (SHA:603207)

Revenue by Segment

Financials in millions CNY. Fiscal year is January - December.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019
Period Ending	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019
Pharmaceuticals	525.28M	474.58M	471.87M	456.89M	401.77M
Pharmaceuticals Growth	10.68%	0.57%	3.28%	13.72%	11.22%
Total	525.28M	474.58M	471.87M	456.89M	401.77M
Total Growth	10.68%	0.57%	3.28%	13.72%	11.22%

Revenue by Geography

Financials in millions CNY. Fiscal year is January - December.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019
Period Ending	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019
East China	182.77M	-	-	169.45M	150.57M
East China Growth	-	-	-	12.54%	2.55%
North China	69.59M	-	-	70.16M	60.86M
North China Growth	-	-	-	15.27%	18.68%
South China	85.52M	-	-	60.50M	53.70M
South China Growth	-	-	-	12.67%	12.44%
Southwest	59.12M	-	-	65.62M	52.26M
Southwest Growth	-	-	-	25.56%	31.16%
Central China	58.87M	-	-	43.53M	36.06M
Central China Growth	-	-	-	20.72%	11.54%
Northeast	45.23M	-	-	45.96M	45.88M
Northeast Growth	-	-	-	0.17%	18.11%
Northwest	23.40M	-	-	14.87M	12.14M
Northwest Growth	-	-	-	22.50%	35.58%
Overseas	210.42K	-	-	-	-
Macao, China	-	-	-	76.90K	-
Unallocated	-	-	-	-13.70M	-10.16M
Total	524.70M	-	-	456.46M	401.29M
Total Growth	-	-	-	13.75%	11.29%

Source: S&P Global Market Intelligence.